CERSI
University of Maryland

Biosimilars: A Decade of Experience and Future Directions

Strategies for Improving Biosimilar Adoption and the Potential Role of Clinical Pharmacology

University of Maryland Center of Excellence in Regulatory Science and Innovation
Food and Drug Administration
Public Webinar
April 13, 2022 | 1:00 – 3:30 pm Eastern Time

Agenda

Leading academic clinicians with specialties in oncology, rheumatology, gastroenterology, and endocrinology will share their experience with biosimilars, their perspectives on how to improve the efficiency of biosimilar evaluations, and how to increase biosimilar adoption, including the role of clinical pharmacology.

1:00 pm – 1:05 pm	**Welcome** **Maureen Kane, PhD** University of Maryland
1:05 pm – 1:10 pm	**Opening Remarks** **Yow-Ming Wang, PhD** Food and Drug Administration
1:10 pm – 1:35 pm	***Biosimilars in Oncology*** **Gary Lyman, MD, MPH, FACP, FRCP (Edin), FASCO** University of Washington
1:35 pm – 2:00 pm	***Biosimilars in Rheumatology (and Immune Mediated Inflammatory Diseases)*** **Allan Gibofsky, MD, JD, MACR, FACP, FCLM** Weill Cornell Medical College
2:00 pm – 2:25 pm	***Biosimilars in IBD: Real World Evidence*** **Gary Lichtenstein, MD, FACP, FACG, AGAF** University of Pennsylvania
2:25 pm – 2:50 pm	***Biosimilar Insulin Concepts*** **Zachary Bloomgarden, MD, MACE, FASPC** Icahn School of Medicine at Mount Sinai
2:50 pm – 3:30 pm	**Panel Discussion**
Moderator	**Raymond Cross, MD, MS, AGAF, FACG** University of Maryland
Panelists	**Yow-Ming Wang, PhD** Food and Drug Administration
	Sarah Yim, MD Food and Drug Administration
	Zachary Bloomgarden, MD, MACE, FASPC Icahn School of Medicine at Mount Sinai
	Allan Gibofsky, MD, JD, MACR, FACP, FCLM Weill Cornell Medical College
	Gary Lichtenstein, MD, FACP, FACG, AGAF University of Pennsylvania
	Gary Lyman, MD, MPH, FACP, FRCP (Edin), FASCO University of Washington